Risk disclosure: Biotech investing involves extreme binary risk including total loss of principal. All tools described provide informational data only and do not constitute investment advice. See our financial disclaimer.
Biotech trading is the highest-variance category in the public markets. A single FDA decision can double or erase a stock overnight. Traders who profit consistently in this space don't try to predict FDA outcomes — they build information advantages around catalyst timing, dilution risk, and cash runway that the broader market doesn't have.
Most retail traders know PDUFA dates exist. What they don't do is track the full regulatory timeline for every company in their watchlist — the complete lifecycle from IND filing to NDA submission to advisory committee to final decision. That full picture determines where a stock is in its risk/reward cycle and how to size a position appropriately.
Professional biotech traders monitor the following event types systematically across their entire universe:
FDA action deadline for NDA/BLA review. The primary binary catalyst for late-stage programs — FDA approves, rejects, or issues a complete response letter by this date.
FDA advisory committee votes — publicly scheduled and typically predictive of the final decision direction. AdCom vote dates are often more tradeable than PDUFA dates due to the longer runway for position building.
Interim and final data from clinical trials. Phase 3 readouts for pivotal trials are high-volatility binary events. Phase 2 data often sets up the PDUFA trajectory 18-24 months later.
FDA rejection with conditions requiring additional data or labeling changes. CRLs are filed as 8-K items within minutes of receipt and are often preceded by unusual trading activity that surveillance tools can flag.
Filing acceptance signals a 6-12 month runway to PDUFA with a defined catalyst timeline. Acceptance dates are disclosed in press releases filed as 8-K exhibits.
Regulatory fast-track designations that shorten review timelines, provide more FDA interaction, and can signal stronger agency alignment with the program's development path.
Even a biotech company with a promising pipeline is a dangerous position if it is approaching a cash cliff near its catalyst window. When a company needs to raise capital to fund operations through a readout, two things happen simultaneously: management faces pressure to time the offering, and existing shareholders face dilution at the worst possible moment — near a high-water mark ahead of a binary event.
Calculating accurate cash runway requires reading quarterly balance sheets, estimating burn rates from operating cash flow statements, and comparing the result against the catalyst timeline. Doing this manually for dozens of biotech positions takes significant time — and most traders skip it entirely.
The calculation is straightforward but needs to be updated every quarter: take cash and equivalents from the balance sheet, divide by the quarterly operating cash burn, and express as months of runway. A biotech with 14 months of runway and a PDUFA date in 8 months is in a structurally different position than one with 6 months of runway facing the same event.
Biotech companies are serial equity issuers by necessity — development programs require continuous funding long before revenue exists. The majority of development-stage biotechs maintain active shelf registrations at all times. Knowing the size of the authorized shelf, the amount already drawn, and whether an ATM agreement is in place helps traders understand whether a stock can sustain a run into a catalyst or whether dilution risk caps the upside at every resistance level.
Key filings to monitor for biotech dilution risk, combined with real-time filing alerts:
The most effective approach to biotech trading treats the portfolio as a collection of defined events with known timelines, each requiring different position sizing and risk management approaches. A position held 90 days ahead of a PDUFA date is managed differently than one entered 5 days before the decision.
Entering 90 days before a PDUFA date gives you time to monitor the regulatory review progress, watch for any FDA communication signals (AdCom meeting additions, label negotiations), and build or reduce the position based on what you learn. It also gives you multiple exit options rather than a forced binary decision at expiration.
When a drug is approved, the attention immediately shifts to launch execution, competitive positioning, and sales ramp. When it's rejected, the CRL conditions determine whether there's a viable path to resubmission and what the timeline looks like. In both cases, the small-cap research tools that got you into the trade continue to provide intelligence on the post-event thesis.
When a major biotech catalyst hits — particularly a high-profile approval or rejection — companies in adjacent therapeutic areas or with similar mechanisms of action often move in sympathy. Understanding which companies are perceived as peers helps traders anticipate and position for these secondary moves before they happen.
BiotechSigns aggregates PDUFA dates from verified regulatory filings, AdCom schedules, Phase 2/3 trial timelines, cash runway estimates, and FDA action history for 950+ small and mid-cap biotech companies. The catalyst calendar updates automatically as new action dates appear in regulatory sources — no manual research required. Combined with DilutionWatch for dilution surveillance, TraderTools Pro subscribers get the complete biotech intelligence stack in one subscription.
PDUFA dates are established when an NDA or BLA is accepted for review by the FDA, typically 60 days after submission. This gives traders 10-12 months of advance visibility from NDA acceptance to the PDUFA date. The company discloses the PDUFA date in its press release announcing filing acceptance — this press release is filed as an 8-K exhibit and is publicly available immediately.
The PDUFA date is the FDA's statutory deadline to complete its review and issue an action (approval or rejection). An advisory committee (AdCom) meeting is a public hearing where external experts vote on questions posed by the FDA — it is not binding but is usually predictive of the final decision. Not all drug applications get AdComs; the FDA selects them for complex or controversial applications.
Cash runway directly impacts dilution risk near catalyst windows. A biotech with less than 12 months of runway approaching a PDUFA date is likely to need additional financing before or after the event, regardless of outcome. This caps upside on approval (because a secondary offering often follows), and compounds downside on rejection (because the company must raise capital in a damaged market). Runway is one of the first metrics to check before building a position.
A complete response letter (CRL) from the FDA indicates the agency found deficiencies requiring additional data or labeling changes before approval can be granted. Stocks typically drop 30-70% on CRL news. What happens next depends on the specific deficiency: chemistry/manufacturing issues are often resolvable; clinical efficacy deficiencies requiring new trials can make a path to approval a multi-year journey. The CRL letter itself is not public, but the company must disclose receipt in an 8-K within four business days.
BiotechSigns is available as part of the TraderTools Pro bundle. Individual platform access may be available — contact the team for current options. The bundle provides the best value for traders who use multiple research tools, as the dilution tracking (DilutionWatch) and supply chain intelligence (ChainSifter) are particularly relevant for biotech positions where dilution risk and customer concentration analysis add meaningful context.